Bonspri 20mg Solution for injection
PDF Leaflet Revision Date: 12 December 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS).
Dosage (summary)
20 mg subcutaneously at weeks 0, 1, 2, then monthly starting week 4.
Special Populations
- Adults over 55 years
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Limited data; may cause fetal B-cell depletion. Use contraception during and 6 months post-treatment.
Key Drug Interactions
- Immunosuppressive therapies
- Live vaccines
Contraindications
- Hypersensitivity to ofatumumab or excipients
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Injection-related reactions
Counselling Points
- Monitor for injection reactions
- Evaluate immune status before treatment
- Avoid live vaccines during treatment
Serious warnings
- Increased risk of infections
- Progressive multifocal leukoencephalopathy (PML) risk
- Hepatitis B virus reactivation
Important Disclaimer
The Bonspri 20mg Solution for injection professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
